Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Gilead to buy CymaBay for $4.3 billion in bets on liver disease treatment

Published 02/12/2024, 08:42 AM
Updated 02/12/2024, 11:10 AM
© Reuters. FILE PHOTO: Gilead Sciences  is seen in Oceanside, California, U.S., April 29, 2020. REUTERS/Mike Blake/File Photo

By Bhanvi Satija

(Reuters) -Gilead Sciences has agreed to buy CymaBay Therapeutics (NASDAQ:CBAY) for $4.3 billion, gaining access to an experimental liver disease treatment with blockbuster potential as the U.S. drugmaker looks beyond its older HIV drugs for growth.

Shares of the Newark, California-based drug developer jumped 24.6% to a record high of $32.01 in morning trading on Monday, compared to the offer price of $32.50 per share. Gilead (NASDAQ:GILD)'s shares rose 1.1% to $74.49.

Gilead will get CymaBay's lead experimental drug, seladelpar, which is estimated to generate sales of $1.9 billion by 2029, if approved, as per LSEG data.

"This transaction helps (Gilead) continue to paint the story for growth beyond their core HIV business," said BMO Capital Markets analyst Evan Seigerman.

The U.S. Food and Drug Administration is reviewing seladelpar as a potential treatment for primary biliary cholangitis, a type of chronic inflammatory liver disease. A decision is expected by Aug. 14.

The deal comes as Gilead has suffered back-to-back setbacks in clinical trials.

Its experimental oral COVID antiviral treatment, obeldesivir, did not meet the main goal in a trial of non-hospitalized patients, while cancer drug Trodelvy failed to significantly improve survival for previously treated patients with a type of lung cancer.

Last week, the U.S. health regulator put a hold on trials testing Gilead's blood cancer drug following increased risk of patient death in some studies.

© Reuters. FILE PHOTO: Gilead Sciences  is seen in Oceanside, California, U.S., April 29, 2020. REUTERS/Mike Blake/File Photo

The company said the deal would complement its portfolio of liver disease drugs, which includes treatments for viral hepatitis.

The transaction, which is expected to close in the first quarter, will be neutral to Gilead's earnings in 2025.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.